Statistical flags indicate unusual patterns — not proof of fraud or wrongdoing. Read our methodology

#9315 of 11K

J1939

Injection, adalimumab-atto biosimilar, twenty milligrams

Injection, adalimumab-atto biosimilar, twenty milligrams is the #9,315 most-billed Medicaid procedure code, with $93 in payments across 249 claims from 2018–2024. The national median cost per claim is $0.15. Costs vary widely — the 90th percentile is $0.51 per claim, 3.4× the median.

Total Paid

$93

0.00% of all spending

Total Claims

249

Providers

4

Avg Cost/Claim

$0

National Cost Distribution

How much do providers bill per claim for J1939? Based on 3 providers billing this code nationally.

Median

$0.15

Average

$0.30

Std Dev

$0.26

Max

$0.60

Percentile Distribution (Cost per Claim)

p10
$0.15
p25
$0.15
Median
$0.15
p75
$0.38
p90
$0.51
p95
$0.55
p99
$0.59

50% of providers bill between $0.15 and $0.38 per claim for this code.

90% bill between $0.15 and $0.51.

Top 1% bill above $0.59.

About This Procedure

HCPCS code J1939 (Injection, adalimumab-atto biosimilar, twenty milligrams) was billed by 4 providers across 249 claims, totaling $93 in Medicaid payments from 2018–2024. This code was used for 164 unique beneficiaries.

Fraud Risk Context

Injectable drug codes carry high per-claim costs and have been involved in drug diversion and upcoding schemes.

Source: HHS OIG Reports

Risk Assessment

Billing Statistics

Median Cost/Claim

$0.15

Providers Billing

3

National Spending

$93

Avg/Median Ratio

2.00×

Highly skewed — outlier-driven

Provider Coverage

We have 3 providers billing this code in our dataset. Individual provider breakdowns are available for top-spending procedure codes.